SCHEMBL17540665

SCHEMBL17540665

CCOC(Cc1ccc(OCC(=NOC)c2cccc(C)c2)cc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 20/20 0.53
PPARG P37231 16/20 0.53
PPARD Q03181 15/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17540671 0.92 PPARA (0.48) PPARAPPARGPPARD
SCHEMBL5801758 0.92 PPARA (0.53) PPARAPPARGPPARD
SCHEMBL5801760 0.92 PPARA (0.53) PPARAPPARGPPARD
SCHEMBL14332212 0.90 PPARA (0.55) PPARAPPARGPPARD
SCHEMBL14332213 0.90 PPARA (0.55) PPARAPPARGPPARD
SCHEMBL17540655 0.86 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL17540676 0.86 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL17540662 0.86 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL17540650 0.86 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL17546466 0.83 PPARA (0.47) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160051529-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES CIRIUS THERAPEUTICS, INC. 2016-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051529-A1 PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES PPARD, PPARG, PPARA PPARA 3/4885PPARG 2/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.